Drug Profile


Alternative Names: (R)-BHCG; A 69992; BMS 180194; C-oxetanocin G; Cyclobut G; Cygalovir; SQ 33054; SQ 34514

Latest Information Update: 19 Feb 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antiretrovirals; Hypoxanthines; Nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cytomegalovirus infections; Hepatitis B; Herpes simplex virus infections; Herpes zoster

Most Recent Events

  • 19 Feb 1999 Discontinued-II for Cytomegalovirus infections in USA (Topical)
  • 19 Feb 1999 Discontinued-III for Hepatitis B in World (PO)
  • 19 Feb 1999 Discontinued-III for Herpes simplex virus infections in World (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top